SCNX_OUT_1 [2025-03-21 12:21:49 -0400] 2538 Bytes | 700 tokens | Cum: 700 tkns (8.75% of 8k)
==========================================================================

We're scouting for winners today. Its 12:21:47 PM on Fri Mar 21, 2025 -0400 and I'm looking at Scienture (SCNX) up to 2.13 from 1.69

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for Scienture:

C1 - Mar-19-25 08:05AM - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
C2 - Mar-18-25 08:05AM - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
C3 - Mar-06-25 07:40AM - SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
C4 - Jan-21-25 08:05AM - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
C5 - Dec-17-24 08:05AM - Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
C6 - Dec-10-24 08:05AM - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
C7 - Nov-26-24 04:05PM - Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement
C8 - Sep-24-24 08:01AM - TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to SCNX

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Scienture (SCNX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SCNX_OUT_3 [2025-03-21 12:21:57 -0400] 1041 Bytes | 322 tokens | Cum: 1024 tkns (12.80% of 8k)
==========================================================================

Showing C2 (chunk 1 of 12): C2:
**SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.**
Date: Mar-18-25 08:05AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3044475/0/en/SCIENTURE-announces-the-U-S-FDA-Approval-of-its-NDA-for-SCN-102-to-be-launched-as-ArbliTM-losartan-potassium-Oral-Suspension-10mg-mL-The-global-market-for-losartan-potassium-was-ap.html

March 18, 2025 08:05 ET| Source:Scienture Holdings, Inc.Scienture Holdings, Inc.

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- –SCIENTURE HOLDINGS, INC.NASDAQ: SCNX),a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_5 [2025-03-21 12:21:59 -0400] 1039 Bytes | 300 tokens | Cum: 1326 tkns (16.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T21:06:24Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Akebia Therapeutics (NASDAQ:AKBA)...
A2 - 2025-03-19T17:06:06Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX)...
A3 - 2025-03-19T12:23:21Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...
A4 - 2025-03-19T12:16:04Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...
A5 - 2025-03-19T12:16:26Z - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Sha...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCNX_OUT_7 [2025-03-21 12:22:00 -0400] 1038 Bytes | 302 tokens | Cum: 1630 tkns (20.38% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Wednesday's After-Market Session - Akebia Therapeutics (NASDAQ:AKBA), Applied DNA Sciences (NASDAQ:APDN)**Date: 2025-03-19Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44406950/12-health-care-stocks-moving-in-wednesdays-after-market-sessionGainers

Brainstorm Cell BCLI shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. Applied DNA Sciences APDN stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. Shuttle Pharmaceuticals SHPH stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. Century Therapeutics IPSC shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. Longevity Hea

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_9 [2025-03-21 12:22:02 -0400] 440 Bytes | 120 tokens | Cum: 1752 tkns (21.90% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-21T13:05:00Z - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_11 [2025-03-21 12:22:06 -0400] 788 Bytes | 218 tokens | Cum: 1972 tkns (24.65% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/21/3012635/0/en/Scienture-Holdings-Inc-Announces-Dr-Narasimhan-Mani-s-Participation-in-the-8th-Annual-Conference-of-The-Society-for-the-Study-of-Xenobiotics.htmlScienture Holdings, Inc., a specialty pharmaceutical company, announced that its President, Dr. Narasimhan Mani, will participate as a speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics in India.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_13 [2025-03-21 12:22:08 -0400] 1115 Bytes | 308 tokens | Cum: 2361 tkns (29.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

S2 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

S3 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_15 [2025-03-21 12:22:09 -0400] 1038 Bytes | 256 tokens | Cum: 2619 tkns (32.74% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01. Entry into a Material Definitive Agreement.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agreement (the Agreement) with Summit Biosciences Inc., a wholly-owned subsidiary of Kindeva Drug Delivery L.P. (Kindeva). Kindeva is a company engaged in the research, development, and manufacturing of pharmaceutical products. Pursuant to the Agreement, Kindeva granted the Company an exclusive, non-transferrable, non-sublicensable right and license to commercialize REZENOPY (Nalaxone HCI Nasal spray 10mg/0.11mL) (the Product) within the United States and its territories. The Company intends to use the exclusive right and license to price, launch, promote, market, distribute, and educate the public on the Product.

Unless earlier terminated, the term of the Agreement will

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_17 [2025-03-21 12:22:11 -0400] 1038 Bytes | 217 tokens | Cum: 2838 tkns (35.48% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): remain in effect for 10 years from the date of first commercial sale of the Product in the United States and its territories to an unaffiliated third-party. The Agreement will automatically renew for successive 1-year periods unless either party terminates the agreement in accordance with its terms. Either party may terminate the Agreement if (i) the other party materially breaches the Agreement and has not cured such breach during a period of 90 days following notice of the breach, (ii) the Product is withdrawn from the market as a result of any ruling or requirement by the United States Food and Drug Administration (the FDA), a voluntary recall by the FDA is issued, or there are material safety concerns that could significantly impact the commercial viability of the Product, or (iii) the Product is the subject of a mass tort liability action or is subject to material health and public

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_19 [2025-03-21 12:22:12 -0400] 1038 Bytes | 217 tokens | Cum: 3057 tkns (38.21% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): safety concerns. The Company may terminate the Agreement upon 120 days prior written notice if the Company determines that the Product is compromised by an adverse and material change in the market or other adverse and material business conditions. The Agreement is also terminable by either party upon the occurrence of certain bankruptcy related events pertaining to the other party.

Pursuant to the Agreement, the Company is exclusively responsible, at its expense, for the commercializing the Product in the United States and its territories in a manner that maximizes the net sales of the Product. The Company has final and sole authority for the pricing of the Product, but has agreed to not reduce the sale price of the Product for reasons other than the impact of market demand for the Product, after taking into account all relevant factors.

Pursuant to the Agreement, Kindeva will reta

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

SCNX_OUT_21 [2025-03-21 12:22:28 -0400] 3877 Bytes | 1076 tokens | Cum: 4135 tkns (51.69% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Volume: 1,366,639 | SMA50: -35.94% | Market Cap: 18.07M | Option/Short: No / No | Sales past 5Y: 18.09% | Sales Surprise: 9.28% |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 2.87M | SMA200: -72.03% | Shs Outstand: 8.61M | Short Float: 0.36% | Employees: 8 | EPS Surprise: -286.67% |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 1.11 | Perf Week: 34.91% | Shs Float: 4.62M | Short Ratio: 0.01 | Debt/Eq: 0.03 | P/E: - |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| RSI (14): 45.38 | Perf Month: -29.47% | Inst Own: 1.04% | Short Interest: 0.02M | Sales Y/Y TTM: -73.19% | Earnings: - |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.52 | Perf Quarter: -74.16% | Insider Own: 48.62% | Beta: 2.74 | ROE: -47.91% | |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+
| SMA20: -0.57% | Index: - | Insider Trans: 0.00% | Sales Q/Q: -96.85% | ROI: -28.75% | |
+-------------------+-----------------------+----------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: Scienture Holdings, Inc. Common Stock
Market Cap: 15194083.58
Shares Outstanding: 8990582
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 64861, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3183601.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.1284
Average Volume: 7623103.09
30-Day High: 2.85
30-Day Low: 1.24

[Detailed Financials: Q3 2024]
- Total Assets: $94,259,693.0
- Total Liabilities: $9,127,652.0
- Total Equity: $85,132,041.0
- Current Assets: $7,255,916.0
- Current Liabilities: $5,413,438.0

[Income Statement: Q3 2024]
- Revenue: $64,861.00
- Net Income: $-3,183,601.0
- Operating Income: $-3,497,791.0
- Earnings Per Share (EPS): -1.34

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-7,140,891.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SCNX_OUT_23 [2025-03-21 12:22:31 -0400] 676 Bytes | 167 tokens | Cum: 4501 tkns (56.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SCNX_IN_25 [2025-03-21 12:22:32 -0400] 126 Bytes | 29 tokens | Cum: 4596 tkns (57.45% of 8k)
==========================================================================

====================================
[2025-03-21 09:22:32] # Analysis Completed
Elapsed Time: 45.41 seconds